At Piper Jaffray, Illumina and Affy Predict Expression Growth in DGE, Clinical Trials | GenomeWeb
This article has been corrected to reflect the accurate pricing of Illumina's 1M BeadChip.
 
While the market for expression arrays is not growing as fast as the genotyping or next-generation sequencing markets, Illumina and Affymetrix both said last week that they see opportunities for further growth in the gene expression sector, via digital gene expression and clinical trials, respectively.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.